Diff-Stat™
The Most Powerful Front Line Defense Against
Antibiotic Associated Diarrhea (AAD) & C-diff
Clostridium difficile (C. diff) is a spore-forming bacterium that releases toxins in the intestine causing mucosal inflammation, intestinal damage, and diarrhea. It is one of the most common nosocomial infections, with incidence and severity on the rise, reaching epidemic levels in the US. This is possibly due to the increased use of broad-spectrum antibiotics and the emergence of a C. diff strain that has increased virulence. Long-term care (LTC) residents are at especially high risk because of extended length of stay, advanced age, frequent hospitalizations, and the widespread use of antibiotics (1). From 50% to 75% of residents in LTC are exposed to 1 or more courses of antibiotics over a 12-month period (2-6). Up to 33% of LTC residents treated with an antibiotic acquire C. diff, with a 44% rate of recurrence within 1-2 months (7, 8). Furthermore, up to 65% of residents who have suffered 2 or more episodes will have another recurrence (8). In the last decade, there has been an increase of antibiotic-associated diarrhea (AAD) of 500%. C .diff accounts for 15% to 25% of all episodes of AAD (9). Even when an outbreak is not occurring, the prevalence of C. diff colonization in LTC ranges up to 20%, compared with less than 3% in healthy adults (10-12).
Click here for References
See the Diff-Stat Difference: Click here to read more.
A recent survey showed that 97% of Residents taking Diff-StatTM while on Antibiotics did not develop AAD & 100% did not develop C-diff!
READ MORE
|
|
